Brief: Onward Medical Sees FDA Submission For ARC-EX System In H1 2024

ONWARD Medical

15/03/2024 06:44

March 15 (Reuters) - Onward Medical NV  ONWD.BR :
    * EXPECTS TO COMMERCIALIZE ITS ARC-EX(®) SYSTEM AND COMMENCE
EMPOWER BP PIVOTAL STUDY FOR ARC-IM(®) SYSTEM IN 2024
    * COMPANY ENDED 2023 WITH EUR 29.8 MLN IN CASH
    * ONWARD® MEDICAL REAFFIRMS GUIDANCE, SHARES 2024 STRATEGIC
PRIORITIES, AND RELEASES UNAUDITED Q4 FINANCIAL HIGHLIGHTS
    * EXPECTS TO ADVANCE CLINICAL AND DEVELOPMENT ACTIVITIES FOR
ITS
UNIQUE ARC-BCITM BRAIN-COMPUTER INTERFACE THERAPY
    * CASH RUNWAY GUIDANCE REAFFIRMED THROUGH YEAR-END 2024
    * NET CASH OUTFLOW IN Q4, 2023 WAS EUR 7.0 MLN
    * HIGHLY CONFIDENT FDA SUBMISSION FOR ITS ARC-EX SYSTEM WILL
OCCUR
IN H1 2024

Source text:  urn:newsml:reuters.com:*:nGNEvXLJ2
Further company coverage:  ONWD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587785110;))